▾ G11 Media Network: | ChannelCity | ImpresaCity | SecurityOpenLab | GreenCity | Italian Channel Awards | Italian Project Awards | ...
InnovationOpenLab

BenevolentAI Announces Further Success With AstraZeneca Collaboration as Novel Heart Failure Target Selected

BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel ...

Business Wire

LONDON: BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target for Heart Failure to its discovery portfolio through its collaboration with BenevolentAI.

  • Novel target for Heart Failure was discovered using BenevolentAI’s AI-drug discovery platform and experimentally validated by AstraZeneca
  • First target to be selected from the extended collaboration with AstraZeneca, highlighting continued positive progress in the field of Target Identification

BenevolentAI’s strategic collaboration with AstraZeneca began in 2019, and originally focused on discovering potential new treatments for idiopathic pulmonary fibrosis (IPF) and chronic kidney disease (CKD). The collaboration was expanded in January 2022 to two new disease areas, Heart Failure and Systemic Lupus Erythematosus (SLE), demonstrating how the Benevolent Platform™ can be applied across multiple therapeutic areas.

The innovative collaboration structure sees scientists and technologists from the two companies work side-by-side, combining BenevolentAI’s AI-driven drug discovery platform and biomedical knowledge with AstraZeneca’s scientific and disease specific expertise, leading to novel and robust Target Identification. Both the initial and extended collaboration were agreed on similar terms with upfront payments on signing, research funding alongside discovery, development and commercial milestones. Additionally, the Company will receive tiered royalties on net sales of any commercialised products.

Heart Failure is a complex syndrome which occurs when the heart cannot pump enough blood around the body. It is often complicated by multiple interrelated diseases, so requires a deep understanding of the potential disease drivers in individual patients. Current heart failure treatments follow a “one-size-fits-all” approach. However, due to the wide range of mechanisms by which heart failure can occur, there remains an unmet need for new therapies as up to 50% of patients die within five years of diagnosis.

Dr Anne Phelan, Chief Scientific Officer of BenevolentAI, said:
“I am delighted that AstraZeneca has selected one of the novel Heart Failure targets that we have been jointly working on to enter its portfolio. Heart Failure is a therapeutic area where there is significant medical need but, due to the size of the market, requires a team effort and significant momentum, so we are delighted to be working with AstraZeneca in this important field of medicine.”

Regina Fritsche Danielson, SVP and Head of Research and Early Development, Cardiovascular, Renal and Metabolism, at AstraZeneca said:
“Our ongoing collaboration with BenevolentAI has been instrumental in uncovering new insights into complex diseases such as CKD and Heart Failure. This shared expertise, combined with the power of AI, has the potential to identify the right therapeutic targets for patients with heart failure and help deliver the next generation of innovative therapies.”

About BenevolentAI

At BenevolentAI (AMS: BAI), we serve patients by leveraging our proprietary and validated Benevolent Platform™ that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery. The Company’s business model presents multiple routes for value creation, including discovery collaborations with pharma companies like AstraZeneca and Merck and advancing in-house pipelines to inflection points. Headquartered in London, with wet labs in Cambridge (UK), BenevolentAI is at the forefront of reshaping the future of drug discovery and delivering innovative medicines.

Category: non-regulatory

Fonte: Business Wire

If you liked this article and want to stay up to date with news from InnovationOpenLab.com subscribe to ours Free newsletter.

Related news

Last News

Gyala: a new "Made in Italy" cybersecurity

With a proven track record in the defence field, Gyala now also brings its cybersecurity technologies to the wider enterprise audience

ITALIAN PROJECT AWARDS 2023: the best IT projects of the year, awarded

Now in its third edition, the initiative is targeted at the ICT professional world and honours projects based on innovative ideas and technologies, realised…

I3P launches the Cybersecurity Incubation Program

The I3P's initiative is promoted together with the National Cybersecurity Agency in collaboration with Leonardo and C*Sparks.

iVis Technologies enables remotely-controlled corneal telesurgery

It's based on Italian technologies the first successful intercontinental telesurgery intervention for keratoconus carried out remotely, connecting Bari…

Most read

NukuDo, a Global Leader in Cybersecurity Workforce Development, Launches…

Today, NukuDo, a global leader in cybersecurity workforce development and staffing, proudly announces the launch of its North American headquarters in…

AmerisourceBergen Specialty Group Provides Substitute Notice of Data Incident…

AmerisourceBergen Specialty Group, LLC (ABSG) is issuing notice to individuals who may have been impacted by a data security incident. ABSG’s parent company…

Latin America Data Center Market Landscape Report 2024-2029 Featuring…

The "Latin America Data Center Market Landscape 2024-2029" report has been added to ResearchAndMarkets.com's offering. The Latin American data center…

TruBridge Announces Participation in the Stifel Cross Sector Insight Conference

TruBridge, Inc. (NASDAQ:TBRG), a healthcare solutions company, today announced that management will participate in the Stifel Cross Sector Insight Conference…

Newsletter signup

Join our mailing list to get weekly updates delivered to your inbox.

Sign me up!